UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pelvic inflammatory disease: Treatment

Author
Harold C Wiesenfeld, MD, CM
Section Editor
Noreen A Hynes, MD, MPH, DTM&H
Deputy Editor
Allyson Bloom, MD

INTRODUCTION

Pelvic inflammatory disease (PID) refers to acute infection of the upper genital tract structures in women, involving any or all of the uterus, fallopian tubes, and ovaries and may involve the neighboring pelvic organs. Early diagnosis and treatment are believed to be key elements in the prevention of long-term sequelae, such as infertility and ectopic pregnancy. (See "Pelvic inflammatory disease: Clinical manifestations and diagnosis".)

The treatment of PID will be reviewed here. The pathogenesis of, risk factors for, and sequelae following PID are discussed separately. The management of tubo-ovarian abscess is discussed separately. (See "Pelvic inflammatory disease: Pathogenesis, microbiology, and risk factors" and "Long-term complications of pelvic inflammatory disease" and "Management and complications of tubo-ovarian abscess".)

INDICATIONS FOR TREATMENT

Clinicians should maintain a low threshold of suspicion for the diagnosis of PID. The presumptive clinical diagnosis of PID is made in sexually active young women or women at risk for sexually transmitted infections (STIs) who present with pelvic or lower abdominal pain and have evidence of cervical motion, uterine, or adnexal tenderness on exam [1]. Occasionally, acute PID may be encountered in women without recent sexual activity. Treatment is indicated for patients with this presumptive clinical diagnosis of PID, even if findings are subtle or minimal, since long-term complications are more common if treatment is withheld or delayed [1,2]. Information regarding the diagnostic criteria for PID is found elsewhere. (See "Pelvic inflammatory disease: Clinical manifestations and diagnosis".)

PATHOGENS OF CONCERN

PID is primarily a disease of sexually active women. The two most important sexually transmitted organisms associated with acute PID, Chlamydia trachomatis and Neisseria gonorrhoeae, should be targeted for treatment; however, negative endocervical screening for either of these pathogens does not rule out upper tract infection [1]. (See "Pelvic inflammatory disease: Pathogenesis, microbiology, and risk factors", section on 'Microbiology'.)

PID is a polymicrobial infection, which generally requires broad coverage, particularly among those with severe disease requiring hospitalization. Acute PID is an ascending infection caused by cervical microorganisms (including C. trachomatis and N. gonorrhoeae), as well as the vaginal microflora, including anaerobic organisms, enteric gram-negative rods, streptococci, genital mycoplasmas, and Gardnerella vaginalis, which is associated bacterial vaginosis [2]. Bacterial vaginosis results in complex alterations of the normal vaginal flora, which may alter host defense mechanisms in the cervicovaginal environment [2-5]. Mycoplasma genitalium is recognized as a cause of urethritis in men, but its role in pelvic inflammatory disease is less well-defined. (See "Mycoplasma genitalium infection in men and women", section on 'Pelvic inflammatory disease'.)

                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Mar 31 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  2. Soper DE. Pelvic inflammatory disease. Obstet Gynecol 2010; 116:419.
  3. Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44 Suppl 3:S111.
  4. Short VL, Totten PA, Ness RB, et al. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis 2009; 48:41.
  5. Walker CK, Workowski KA, Washington AE, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. Clin Infect Dis 1999; 28 Suppl 1:S29.
  6. Walker CK, Kahn JG, Washington AE, et al. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. J Infect Dis 1993; 168:969.
  7. Dodson MG. Antibiotic regimens for treating acute pelvic inflammatory disease. An evaluation. J Reprod Med 1994; 39:285.
  8. Judlin P, Liao Q, Liu Z, et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117:1475.
  9. Hemsell DL, Little BB, Faro S, et al. Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease. Clin Infect Dis 1994; 19:720.
  10. Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.
  11. Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin Infect Dis 1997; 24:170.
  12. Rein DB, Kassler WJ, Irwin KL, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol 2000; 95:397.
  13. Bohm MK, Newman L, Satterwhite CL, et al. Pelvic inflammatory disease among privately insured women, United States, 2001-2005. Sex Transm Dis 2010; 37:131.
  14. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186:929.
  15. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525.
  16. Drugs for sexually transmitted infections. Treat Guidel Med Lett 2004; 2:67.
  17. McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994; 83:998.
  18. Comparative evaluation of clindamycin/gentamicin and cefoxitin/doxycycline for treatment of pelvic inflammatory disease: a multi-center trial. The European Study Group. Acta Obstet Gynecol Scand 1992; 71:129.
  19. Landers DV, Wolner-Hanssen P, Paavonen J, et al. Combination antimicrobial therapy in the treatment of acute pelvic inflammatory disease. Am J Obstet Gynecol 1991; 164:849.
  20. Wasserheit JN, Bell TA, Kiviat NB, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Intern Med 1986; 104:187.
  21. Brunham RC, Binns B, Guijon F, et al. Etiology and outcome of acute pelvic inflammatory disease. J Infect Dis 1988; 158:510.
  22. Livengood CH 3rd, Hill GB, Addison WA. Pelvic inflammatory disease: findings during inpatient treatment of clinically severe, laparoscopy-documented disease. Am J Obstet Gynecol 1992; 166:519.
  23. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 2003; 31:45.
  24. Savaris RF, Teixeira LM, Torres TG, et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol 2007; 110:53.
  25. Zeger W, Holt K. Gynecologic infections. Emerg Med Clin North Am 2003; 21:631.
  26. Thompson SE, Brooks C, Eschenbach DA, et al. High failure rates in outpatient treatment of salpingitis with either tetracycline alone or penicillin/ampicillin combination. Am J Obstet Gynecol 1985; 152:635.
  27. Brookoff D. Compliance with doxycycline therapy for outpatient treatment of pelvic inflammatory disease. South Med J 1994; 87:1088.